There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
PTC Therapeutics (PTCT)
William Blair analyst Sami Corwin maintained a Buy rating on PTC Therapeutics today. The company’s shares closed last Monday at $29.99.
According to TipRanks.com, Corwin is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for PTC Therapeutics with a $27.18 average price target, implying a -2.3% downside from current levels. In a report released yesterday, Wells Fargo also initiated coverage with a Buy rating on the stock with a $37.00 price target.
See the top stocks recommended by analysts >>
Regeneron (REGN)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Regeneron yesterday and set a price target of $980.00. The company’s shares closed last Monday at $902.88, close to its 52-week high of $924.89.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $945.42, representing a 6.2% upside. In a report issued on December 26, Oppenheimer also maintained a Buy rating on the stock with a $1125.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PTCT:
- PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
- Amgen upgraded, PepsiCo downgraded: Wall Street’s top analyst calls
- PTC Therapeutics downgraded to Underweight at Morgan Stanley
- PTC Therapeutics initiated with an Overweight at Wells Fargo
- PTC Therapeutics initiated with bullish view at Wells Fargo
